Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2

被引：0
|
作者：
Zammarchi, Francesca
Havenith, Karin
Leatherdale, Ben
Roberts, Britanny
Montolio, Lara
Patel, Afroze
Janghra, Narinder
Alves, Pedro
Zaitseva, Kristina
Kirby, Cecile Oblette Ian
de Haan, Lolke
van Berkel, Patrick H.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1604
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1604
引用
收藏
页数：3
相关论文
共 43 条
  • [31] Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
    Scribner, Juniper A.
    Brown, Jennifer G.
    Son, Thomas
    Chiechi, Michael
    Li, Pam
    Sharma, Sharad
    Li, Hua
    De Costa, Anushka
    Li, Ying
    Chen, Yan
    Easton, Ann
    Yee-Toy, Nicholas C.
    Chen, Francine Z.
    Gorlatov, Sergey
    Barat, Bhaswati
    Huang, Ling
    Wolff, Christina R.
    Hooley, Jeff
    Hotaling, Tim E.
    Gaynutdinov, Timur
    Ciccarone, Valentina
    Tamura, James
    Koenig, Scott
    Moore, Paul A.
    Bonvini, Ezio
    Loo, Deryk
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2235 - 2244
  • [32] Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors
    Doi, Toshihiko
    Iwata, Hiroji
    Tsurutani, Junji
    Takahashi, Shunji
    Park, Haeseong
    Redfern, Charles H.
    Shitara, Kohei
    Shimizu, Chikako
    Taniguchi, Hiroya
    Iwasa, Tsutomu
    Taira, Shinichiro
    Lockhart, Albert C.
    Fisher, Jennifer M.
    Jikoh, Takahiro
    Fujisaki, Yoshihiko
    Lee, Caleb C.
    Yver, Antoine
    Tamura, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
    Capone, Emily
    Lattanzio, Rossano
    Gasparri, Fabio
    Orsini, Paolo
    Rossi, Cosmo
    Iacobelli, Valentina
    De Laurenzi, Vincenzo
    Natali, Pier Giorgio
    Valsasina, Barbara
    Iacobelli, Stefano
    Sala, Gianluca
    PHARMACEUTICS, 2021, 13 (04)
  • [34] Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers
    Pore, Nabendu
    Schifferli, Kevin P.
    Monks, Noel R.
    Tammali, Ravinder
    Borrok, Martin
    Hurt, Elaine
    Flynn, Matt
    Rebelatto, Marlon
    Townsley, Danielle M.
    Hinrichs, Mary Jane
    Dixit, Rakesh
    Coats, Steven
    Herbst, Ronald
    Tice, David
    BLOOD, 2018, 132
  • [35] SO-N102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels.
    Sadilkova, Lenka Kyrych
    Valentova, Iva
    Hoskova, Simona
    Vopalensky, Pavel
    Bammert, Lukas
    Beerli, Roger
    Moebius, Ulrich
    Spisek, Radek
    CANCER RESEARCH, 2021, 81 (13)
  • [36] Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
    Wang, Zeng
    Zheng, Meijun
    Li, Mengyao
    Lu, Huaqing
    Liu, Nanxi
    Chen, Yongdong
    Yang, Nian
    Zeng, Wanqin
    Dong, Yijun
    Li, Jia
    Zhu, Zhixiong
    Yang, Chen
    Zhang, Zongliang
    Lu, Qizhong
    Li, Hexian
    Zhou, Liangxue
    Yang, Hui
    Tong, Aiping
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 261 - 274
  • [37] NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors-A phase 1/2 clinical trial.
    Tolcher, Anthony W.
    Meric-Bernstam, Funda
    McKean, Meredith
    Beerli, Roger R.
    Waldmeier, Lorenz
    Gebleux, Remy
    Hellmann, Ina
    Chrom, Pawel
    Grawunder, Ulf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
    Meric-Bernstam, Funda
    Calvo, Emiliano
    Lee, Keun Seok
    Moreno, Victor
    Park, Yeon Hee
    Rha, Sun Young
    Chalasani, Pavani
    Zhong, Wei
    Zhou, Li
    Pirie-Shepherd, Steven
    Leung, Abraham C. F.
    Curigliano, Giuseppe
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (10) : 1191 - 1203
  • [39] A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
    Bergstrom, Donald A.
    Bodyak, Natalya
    Yurkovetskiy, Alex
    Park, Peter U.
    DeVit, Michael
    Yin, Mao
    Poling, Laura
    Thomas, Joshua D.
    Gumerov, Dmitry
    Xiao, Dongmei
    Ter-Ovanesyan, Elena
    Qin, LiuLiang
    Uttard, Alex
    Johnson, Alex
    Lowinger, Timothy B.
    CANCER RESEARCH, 2015, 75
  • [40] Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
    Hamilton, Erika Paige
    Barve, Minal A.
    Bardia, Aditya
    Beeram, Muralidhar
    Bendell, Johanna C.
    Mosher, Rebecca
    Hailman, Eric
    Bergstrom, Donald Alan
    Burris, Howard A.
    Soliman, Hatem Hussein
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345